News

Relacorilant administered in combination with nab-paclitaxel elicited responses in patients with metastatic pancreatic cancer, leading to the halting of enrollment in the phase 2 RELIANT trial.

Rachel Wuerstein, MD, discusses the clinical implications of the results of the KAMILLA trial, which evaluates the benefit of trastuzumab emtansine in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.

New published data from a phase 2/3 trial shows the increased survival benefit of PD-1 inhibitor sintililmab and bevacizumab biosimilar IBI305 in the frontline setting for patients with metastatic HCC.

Intensifying daratumumab induction therapy may improve responses to therapy in patients with ultra­ high-risk multiple myeloma or primary plasma cell leukemia, according to prospective study results.

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the current standard of care for EGFR exon 20 insertion-mutated lung cancer.

Sintilimab injection in combination with chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival as frontline treatment of patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma.

In an interview with Targeted Oncology, Kathleen Moore, MD, discusses the effects of niraparib for ovarian cancer in the earlier-line setting in more detail and how she anticipates it will change clinical practice. 

Newer immunotherapy approaches continue to be explored to treat patients with relapsed or refractory MCC after PD-1/ PD-L1 inhibition.

The in-house oral oncolytic pharmacy of American Oncology Network, LCC, received reaccreditation from the Accreditation Commission for Health Care.

The investigational next-generation tyrosine kinase inhibitor, taletrectinib has been dosed for the first time in a patient with an NTRK fusion-positive solid tumor being treated in a phase 2 study.

The combination of the anti-PD-1/PD-L1 therapy pembrolizumab with the platinum-based chemotherapy regimens paclitaxel plus cisplatin or paclitaxel plus carboplatin administered with or without bevacizumab improved both progression-free and overall survival in patients with persistent, recurrent, or metastatic cervical cancer, meeting the primary end point of the phase 3 KEYNOTE-826 trial.

Caron A. Jacobson, MD, MMSc, discusses the design of the phase 2 ZUMA-5 trial, which evaluated the efficacy of axicabtagene ciloleucel in relapsed/refractory indolent Non-Hodgkin Lymphoma.

In an interview with Targeted Oncology, Peter Riedell, MD, discussed an analysis of how time to relapse impacts survival. He also explained what the study findings mean for clinical practice.

The use of daratumumab as maintenance therapy for patients with newly diagnosed multiple myeloma who received autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone was beneficial.

Richard Finn, MD, professor of Medicine at the Geffen School of Medicine at the University of California Los Angeles, discusses both the recent advances and remaining unmet needs in hepatocellular carcinoma.

Results from the LYRA trial showed that the combination of daratumumab with cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses in patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant status.

A supplemental new drug application has been submitted to the FDA seeking approval for the combination of copanlisib and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin’s Lymphoma and is outside of the FDA accelerated approved indication for the treatment of relapsed follicular lymphoma who have received at least 2 prior systemic therapies.

Gettysburg Cancer Center, with clinics in Gettysburg and Hanover, PA, will join OneOncology, the national platform for independent community oncology practices, OneOncology announced.

The Association of Community Cancer Centers announced the launch of CANCER BUZZ TV, its video podcast channel aimed at informing oncology professionals of the latest developments in cancer care.

A nonrandomized phase 2 trial of ibrutinib plus venetoclax in patients with treatment naïve chronic lymphocytic leukemia showed durable remissions after more than 3 years of follow-up.

Type C meeting responses from the FDA have led to the finalization of the clinical development approach of STAR-OLZ, a multi-day transdermal olanzapine patch, for the treatment of chemotherapy induced nausea and vomiting.

The FDA has granted an orphan drug designation to gunagratinib (ICP-192) for the treatment of cholangiocarcinoma.

The FDA has granted breakthrough therapy designation to 177Lu-PSMA-617, an investigational radioligand therapy for the treatment of metastatic castration-resistant prostate cancer.

The FDA has accepted the biologics license application for the anti-PD-1 antibody drug balstilimab for the treatment of recurrent of metastatic cervical cancer with disease progression on or after chemotherapy.

The FDA approved the use of avapritinib for patients with advanced systemic mastocytosis, aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.

During a Targeted Oncology Case-Based Roundtable event, Mark A. Socinski, MD, discussed the case of a 59-year-old patients with non–small cell lung cancer.

In an interview with Targeted Oncology, Peter Hillmen, MD, PhD, discussed the results of the head-to-head trial comparing acalabrutinib and ibrutinib, as well as future directions for Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.

In an interview with Targeted Oncology, held during the 2021 ASCO Annual Meeting, Travis Sims, MD, MPH, discussed the treatment of HRD-positive ovarian cancer and the retrospective analysis of HRD status and its impact of survival outcomes for this patient population.

Treatment with [vic-]trastuzumab duocarmazine (SYD985) demonstrated a statistically significant improvement in progression-free survival compared with physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP study, according to a press release from Byondis B.V.

Subgroup analyses from the the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials show that achievement of transfusion independence by the 24th week of treatment is associated with an improvement in overall survival compared with continued transfusion dependence at that time point.